Great Point Partners LLC Cut Stake in Foamix Pharmaceuticals LTD (FOMX) as Share Price Declined

Great Point Partners Llc decreased its stake in Foamix Pharmaceuticals Ltd (FOMX) by 21.77% based on its latest 2019Q2 regulatory filing with the SEC. Great Point Partners Llc sold 587,062 shares as the company’s stock declined 25.08% . The hedge fund held 2.11 million shares of the specialty chemicals company at the end of 2019Q2, valued at $5.02B, down from 2.70 million at the end of the previous reported quarter. Great Point Partners Llc who had been investing in Foamix Pharmaceuticals Ltd for a number of months, seems to be less bullish one the $209.85 million market cap company. The stock increased 0.58% or $0.02 during the last trading session, reaching $3.44. About 344,811 shares traded. Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) has declined 58.36% since September 13, 2018 and is downtrending. It has underperformed by 58.36% the S&P500.

Great Point Partners Llc, which manages about $935.83 million and $900.81 billion US Long portfolio, upped its stake in Audentes Therapeutics Inc. by 350,319 shares to 1.92M shares, valued at $72.80B in 2019Q2, according to the filing. It also increased its holding in Dermira Inc. (NASDAQ:DERM) by 997,600 shares in the quarter, for a total of 1.55M shares, and has risen its stake in Momenta Pharmaceuticals Inc. (NASDAQ:MNTA).

Analysts await Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) to report earnings on November, 6. They expect $-0.34 earnings per share, up 10.53 % or $0.04 from last year’s $-0.38 per share. After $-0.35 actual earnings per share reported by Foamix Pharmaceuticals Ltd. for the previous quarter, Wall Street now forecasts -2.86 % EPS growth.

More notable recent Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) news were published by: which released: “Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2019 – GlobeNewswire” on March 08, 2019, also with their article: “Foamix Pharma down 5% after hours on stock sales deal – Seeking Alpha” published on August 19, 2019, published: “Foamix Announces Appointment of Sharon Barbari to Board of Directors – GlobeNewswire” on January 23, 2019. More interesting news about Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) were released by: and their article: “Foamix Announces Publication of Phase 3 FMX101 Acne Study in Journal of American Academy of Dermatology – GlobeNewswire” published on June 04, 2019 as well as‘s news article titled: “Analysts Predict 29% Upside For The Holdings of IBB – Nasdaq” with publication date: July 11, 2019.

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.